Jeong Won Jang
Overview
Explore the profile of Jeong Won Jang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
205
Citations
2491
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yim H, Seo Y, Kim J, Kim W, Jung Y, Jang J, et al.
Clin Mol Hepatol
. 2025 Jan;
PMID: 39828249
Background/aims: Besifovir (BSV) showed comparable antiviral activity superior safety profiles to tenofovir disoproxil fumarate (TDF) in treatment-naïve chronic hepatitis B (CHB). However, no data are available regarding the antiviral efficacy...
2.
Kim J, Kim H, Tak K, Han J, Nam H, Sung P, et al.
Clin Mol Hepatol
. 2025 Jan;
PMID: 39743888
Background/aims: Hepatocellular carcinoma (HCC) exhibits significant sex disparities in incidence, yet its molecular mechanisms remain unclear. We explored the role of telomerase reverse transcriptase (TERT) genetic alterations and hepatitis B...
3.
Lee J, Lee J, Kim S, Yoo J, Kim J, Yang K, et al.
Front Oncol
. 2024 Dec;
14:1495321.
PMID: 39726713
Background: There is no established second-line treatment for hepatocellular carcinoma (HCC) following atezolizumab-bevacizumab (ate-beva) failure. This study assessed the efficacy of hepatic arterial infusion chemotherapy (HAIC) as a salvage therapy...
4.
Lee J, Yoo J, Kim J, Lee D, Yang K, Kim B, et al.
Front Immunol
. 2024 Dec;
15:1506355.
PMID: 39720711
Background: Programmed death-ligand 1 (PD-L1) expression is abundant not only in malignant cells but also in infiltrating cells within the tumor microenvironment (TME) of hepatocellular carcinoma (HCC). This study explored...
5.
Cha J, Park N, Cho S, Nam H, Yang H, Jung E, et al.
Front Immunol
. 2024 Oct;
15:1444100.
PMID: 39381000
Background: Metabolic dysfunction-associated steatohepatitis (MASH) is characterized by persistent inflammatory cascades, with macrophage activation playing a pivotal role. Chitinase 1 (CHIT1), produced by activated macrophages, is a key player in...
6.
Lee S, Kwon J, Jang J, Bae S, Yoon S, Jung E, et al.
Transplantation
. 2024 Oct;
PMID: 39375899
Liver transplantation (LT) is the ultimate treatment for patients with end-stage liver disease or early hepatocellular carcinoma. In the context of LT, because of the unique immunological characteristics of human...
7.
Lee S, Choi H, You Y, Sung P, Yoon S, Jang J, et al.
Clin Mol Hepatol
. 2024 Oct;
31(1):131-146.
PMID: 39355872
Background/aims: This study aimed to identify the risk factors for chronic kidney disease (CKD) and end-stage renal disease (ESRD) following liver transplantation (LT), with a specific focus on tacrolimus levels...
8.
Lee S, Park S, Park S, Lee S, Cho B, Eom K, et al.
Diagnostics (Basel)
. 2024 Aug;
14(16).
PMID: 39202234
Hepatic graft-versus-host disease (GVHD) significantly impacts morbidity and mortality among allogeneic hematopoietic stem cell transplant recipients. However, the relationship between clinical and immunopathological phenotypes and their influence on clinical outcomes...
9.
Han J, Sohn W, Choi G, Jang J, Seo G, Kim B, et al.
J Liver Cancer
. 2024 Aug;
24(2):274-285.
PMID: 39187270
Backgrounds/aims: The treatment landscape for hepatocellular carcinoma (HCC) has significantly evolved over the past decade. We aimed to analyze trends in treatment patterns for HCC using a nationwide claims database...
10.
Nam H, Lee J, Han J, Lee S, Yang H, Lee H, et al.
Liver Cancer
. 2024 Aug;
13(4):413-425.
PMID: 39114756
Introduction: Despite the emergence of atezolizumab and bevacizumab (A + B) as standard first-line systemic therapy for unresectable hepatocellular carcinoma (HCC), a comprehensive understanding of the clinical significance of immune-related...